Citigroup
RXRX icon

Citigroup’s Recursion Pharmaceuticals RXRX Stock Holding History

Citigroup’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,000
Closed -$123K – 6332
2025
Q4 		$123K Buy
+30,000
New +$149K ﹤0.01% 4233
2025
Q1 		– Sell
-22,100
Closed -$149K – 5910
2024
Q4 		$149K Buy
+22,100
New +$149K ﹤0.01% 4615

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup's RXRX Position: Q1 2026 in Review

Citigroup increased its Recursion Pharmaceuticals (RXRX) stake by 7.2% in Q1 2026, buying an estimated $47.6K and bringing the position to 182,610 shares worth $561K. The position accounts for ﹤0.01% of the portfolio, ranked #3479.

Citigroup first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $7.99M in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Citigroup held 182,610 shares of Recursion Pharmaceuticals worth $561K as of Q1 2026.
  • Citigroup bought 12,323 Recursion Pharmaceuticals shares in Q1 2026, an estimated $47.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3479 holding.
  • Citigroup first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Citigroup's Recursion Pharmaceuticals position peaked at $7.99M in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.